Land: Bandaríkin
Tungumál: enska
Heimild: NLM (National Library of Medicine)
ZOLPIDEM TARTRATE (UNII: WY6W63843K) (ZOLPIDEM - UNII:7K383OQI23)
NCS HealthCare of KY, Inc dba Vangard Labs
ZOLPIDEM TARTRATE
ZOLPIDEM TARTRATE 5 mg
ORAL
PRESCRIPTION DRUG
Zolpidem Tartrate Tablets USP are indicated for the short-term treatment of insomnia characterized by difficulties with sleep initiation. Zolpidem Tartrate Tablets USP have been shown to decrease sleep latency for up to 35 days in controlled clinical studies [see Clinical Studies (14) ]. The clinical trials performed in support of efficacy were 4 to 5 weeks in duration with the final formal assessments of sleep latency performed at the end of treatment. Zolpidem tartrate is contraindicated in patients with known hypersensitivity to zolpidem. Observed reactions include anaphylaxis and angioedema [see Warnings and Precautions (5.3)] . Teratogenic Effects Pregnancy Category C There are no adequate and well-controlled studies of zolpidem tartrate in pregnant women. Studies in children to assess the effects of prenatal exposure to zolpidem have not been conducted; however, cases of severe neonatal respiratory depression have been reported when zolpidem was used at the end of pregnancy, especially when taken with
Zolpidem tartrate tablets USP are available as follows: 5 mg: pink, film-coated, round, unscored tablets, debossed "TEVA" on one side of the tablet and “73” on the other. They are available in blistercards of 30 (NDC 0615-8046-39). 10 mg: white to off-white, film-coated, round, unscored tablets, debossed "TEVA" on one side of the tablet and “74” on the other. They are available in blistercards of 30 (NDC 0615-8047-39). Store at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature]. Dispense in a tight, light-resistant container as defined in the USP, with a child-resistant closure (as required). KEEP THIS AND ALL MEDICATIONS OUT OF THE REACH OF CHILDREN.
Abbreviated New Drug Application
ZOLPIDEM TARTRATE- ZOLPIDEM TARTRATE TABLET, FILM COATED NCS HealthCare of KY, Inc dba Vangard Labs ---------- MEDICATION GUIDE ZOLPIDEM TARTRATE (zol PI dem tar trate) Tablets USP CIV Read the Medication Guide that comes with zolpidem tartrate tablets before you start taking them and each time you get a refill. There may be new information. This Medication Guide does not take the place of talking to your healthcare provider about your medical condition or treatment. What is the most important information I should know about zolpidem tartrate tablets? • •Do not take more zolpidem tartrate tablets than prescribed. • •Do not take zolpidem tartrate tablets unless you are able to stay in bed a full night (7 to 8 hours) before you must be active again. • •Take zolpidem tartrate tablets right before you get in bed, not sooner. Zolpidem tartrate tablets may cause serious side effects, including: • •After taking zolpidem tartrate tablets, you may get up out of bed while not being fully awake and do an activity that you do not know you are doing. The next morning, you may not remember that you did anything during the night. You have a higher chance for doing these activities if you drink alcohol or take other medicines that make you sleepy with zolpidem tartrate tablets. Reported activities include: • •driving a car (“sleep-driving”) • •making and eating food • •talking on the phone • •having sex • •sleep-walking Call your healthcare provider right away if you find out that you have done any of the above activities after taking zolpidem tartrate tablets. Do not take zolpidem tartrate tablets if you: • •drank alcohol that evening or before bed • •took another medicine to help you sleep What is zolpidem tartrate? Zolpidem tartrate is a sedative-hypnotic (sleep) medicine. Zolpidem tartrate is used in adults for the short- term treatment of a sleep problem called insomnia (trouble falling asleep). It is not known if zolpidem tartrate is safe and effective in children under the a Lestu allt skjalið
ZOLPIDEM TARTRATE- ZOLPIDEM TARTRATE TABLET, FILM COATED NCS HEALTHCARE OF KY, INC DBA VANGARD LABS ---------- HIGHLIGHTS OF PRESCRIBING INFORMATION THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE ZOLPIDEM TARTRATE TABLETS USP SAFELY AND EFFECTIVELY. SEE FULL PRESCRIBING INFORMATION FOR ZOLPIDEM TARTRATE TABLETS USP. ZOLPIDEM TARTRATE TABLETS, FOR ORAL USE CIV INITIAL U.S. APPROVAL: 1992 RECENT MAJOR CHANGES Warnings and Precautions, Severe Injuries (5.8) 10/2014 INDICATIONS AND USAGE Zolpidem Tartrate Tablets USP, a gamma-aminobutyric acid (GABA) A agonist, are indicated for the short-term treatment of insomnia characterized by difficulties with sleep initiation. Zolpidem Tartrate Tablets USP have been shown to decrease sleep latency for up to 35 days in controlled clinical studies. (1) DOSAGE AND ADMINISTRATION •Use the lowest dose effective for the patient (2.1) •Recommended initial dose is 5 mg for women and 5 or 10 mg for men, immediately before bedtime with at least 7 to 8 hours remaining before the planned time of awakening (2.1) •Geriatric patients and patients with hepatic impairment: Recommended dose is 5 mg for men and women (2.2) •Lower doses of CNS depressants may be necessary when taken concomitantly with zolpidem tartrate tablets (2.3) •The effect of zolpidem tartrate tablets may be slowed if taken with or immediately after a meal (2.4) DOSAGE FORMS AND STRENGTHS 5 mg and 10 mg tablets. Tablets not scored. (3) CONTRAINDICATIONS Known hypersensitivity to zolpidem (4) WARNINGS AND PRECAUTIONS •CNS depressant effects: Impairs alertness and motor coordination. Instruct patients on correct use. (5.1) •Need to evaluate for co-morbid diagnosis: Reevaluate if insomnia persists after 7 to 10 days of use. (5.2) •Severe anaphylactic/anaphylactoid reactions: Angioedema and anaphylaxis have been reported. Do not rechallenge if such reactions occur. (5.3) •“Sleep-driving” and other complex behaviors while not fully awake. Risk increases with dose and use with other CNS dep Lestu allt skjalið